ArticleVirchows Archiv : an international journal of pathology2026
Histopathological characteristics of screen-detected colorectal cancers.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Guidance for laboratory implementation, governance and continuous assurance of artificial intelligence in histopathology.Virchows Archiv : an international journal of pathology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Screen-detected colorectal cancers (CRCs) represent an increasing proportion of diagnoses as population screening is expanded. They are associated with improved prognosis compared to non-screening cases even when adjusted for stage. We aimed to evaluate the histopathological features and impact on survival of faecal immunochemical test (FIT)-based screen-detected CRCs with comparison to a cohort of non-screening cases. We analysed a database of screen-detected CRCs (n = 191) in our institution since screening began in 2012 with comparison to a cohort of non-screening cases (2019-2020, n = 358). Histopathological reports were reviewed for prognostic factors such as lymphovascular invasion (LVI), perineural invasion (PNI) and tumour budding. The patient record was reviewed for survival analysis. Screen-detected CRCs were associated with an earlier stage of diagnosis (p = 0.002) and had lower rates of serosal involvement (T4) (20% vs 33%, p = 0.001), PNI (7% vs 16%, p = 0.002) and extramural venous invasion (EMVI) (11% vs 29%, p < 0.0001). Screen-detected rectal cancers also had higher complete response rates to neoadjuvant therapy (42% vs 17%, p = 0.024). Overall survival was superior in screening cases (χ
Indexed as
Identifiers
42118289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.